Transplantation outcomes
| . | Filgrastim . | Control . |
|---|---|---|
| Day discharged | 16 (10-42)4-150 | 20 (10-80)4-151 |
| Gr 2-4 mucosal RRT | 5/21‡ | 9/21 |
| Gr 2-4 maximal RRT | 10/21 | 13/21 |
| Gr 3-4 maximal RRT | 0/21 | 2/21 |
| Day 30 TRM | 1/21 | 0/21 |
| Day 100 TRM4-153 | 1/21 | 5/21 |
| Gr 2-4 GVHD (%) | 27 (7-48)4-155 | 34 (13-55) |
| Gr 3-4 GVHD (%) | 12 (0-28) | 20 (2-37) |
| Chronic GVHD (%) | 79 (54-100) | 60 (31-89) |
| Relapse at 1 y (%) | 62 (40-84) | 46 (19-74) |
| Survival at 1 y (%) | 60 (38-82) | 54 (31-77) |
| . | Filgrastim . | Control . |
|---|---|---|
| Day discharged | 16 (10-42)4-150 | 20 (10-80)4-151 |
| Gr 2-4 mucosal RRT | 5/21‡ | 9/21 |
| Gr 2-4 maximal RRT | 10/21 | 13/21 |
| Gr 3-4 maximal RRT | 0/21 | 2/21 |
| Day 30 TRM | 1/21 | 0/21 |
| Day 100 TRM4-153 | 1/21 | 5/21 |
| Gr 2-4 GVHD (%) | 27 (7-48)4-155 | 34 (13-55) |
| Gr 3-4 GVHD (%) | 12 (0-28) | 20 (2-37) |
| Chronic GVHD (%) | 79 (54-100) | 60 (31-89) |
| Relapse at 1 y (%) | 62 (40-84) | 46 (19-74) |
| Survival at 1 y (%) | 60 (38-82) | 54 (31-77) |
RRT indicates regiment-related toxicity; TRM, treatment-related mortality; GVHD, graft-versus-host disease; CI, confidence interval.
Median (range).
P = .05 for comparison between filgrastim and control groups. No other significant differences existed between the groups.
Number of patients/number evaluable.
One patient in the filgrastim arm died of infection. In the control arm, 4 patients died of GVHD and infection, and 1 patient died of graft failure and infection.
Kaplan-Meier estimate (95% CI).